PMID- 31068754
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1178-623X (Print)
IS  - 1178-623X (Electronic)
IS  - 1178-623X (Linking)
VI  - 12
DP  - 2019
TI  - The Evolving Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation 
      of Systemic Amyloidosis.
PG  - 1178623X19843519
LID - 10.1177/1178623X19843519 [doi]
LID - 1178623X19843519
AB  - Systemic amyloidosis is a serious multiorgan disease with reduced life 
      expectancy, irrespective of type. The impact of magnetic resonance imaging (MRI) 
      in managing this condition has been immense. The last decade in particular has 
      seen a surge of interest in the assessment and evaluation of the heart in 
      patients with systemic amyloidosis by cardiovascular magnetic resonance imaging 
      (CMR), with approximately 85% of all publications on this subject arising in the 
      last 10 years. This has been largely driven by the creation of new sequences and 
      their subsequent modernisation and technical development, thereby rendering 
      previously prohibitive methods clinically more relevant and applicable. In turn, 
      this has led to an increased awareness and recognition of the disease. This 
      review demonstrates how MRI has become a pivotal diagnostic tool in the 
      assessment of cardiac amyloidosis over the last 2 decades, with the ability to 
      track disease and predict mortality. Several different pathognomonic patterns of 
      late gadolinium enhancement (LGE) are now recognised and are able to 
      prognosticate. T1 mapping and extracellular volume (ECV) techniques have resulted 
      in even earlier disease detection before LGE is even visible and along with T2 
      mapping, provide new insights into biology. As newer therapies also evolve and 
      become available, the need for accurate tracking of cardiac disease response to 
      treatment carries increasing importance. All these are examined in this review, 
      mainly focussing on light-chain (AL) and transthyretin (ATTR) amyloidosis.
FAU - Banypersad, Sanjay M
AU  - Banypersad SM
AD  - Royal Blackburn Hospital, Blackburn, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190501
PL  - United States
TA  - Magn Reson Insights
JT  - Magnetic resonance insights
JID - 101512633
PMC - PMC6495435
OTO - NOTNLM
OT  - Amyloidosis
OT  - CMR
OT  - Cardiac MRI
OT  - ECV
OT  - Late gadolinium enhancement,LGE
OT  - T1 mapping
OT  - T2 mapping
COIS- Declaration of conflicting interests:The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2019/05/10 06:00
MHDA- 2019/05/10 06:01
PMCR- 2019/05/01
CRDT- 2019/05/10 06:00
PHST- 2019/01/19 00:00 [received]
PHST- 2019/03/19 00:00 [accepted]
PHST- 2019/05/10 06:00 [entrez]
PHST- 2019/05/10 06:00 [pubmed]
PHST- 2019/05/10 06:01 [medline]
PHST- 2019/05/01 00:00 [pmc-release]
AID - 10.1177_1178623X19843519 [pii]
AID - 10.1177/1178623X19843519 [doi]
PST - epublish
SO  - Magn Reson Insights. 2019 May 1;12:1178623X19843519. doi: 
      10.1177/1178623X19843519. eCollection 2019.